AbbVie Inc. has settled its Delaware patent infringement suit against Boehringer Ingelheim, granting the German drugmaker a nonexclusive license to begin selling a biosimilar of its $20 billion immunosuppressant Humira in 2023.

The companies announced the settlement with a pair of press releases Tuesday. Under the agreement, Boehringer will to pay AbbVie royalties for licensing its Humira patents and agreed to acknowledges the validity and enforceability of the patents, AbbVie said.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]